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BRIEF COMMUNICATION
Challenges and standardization of microRNA 
profiling in serum and cerebrospinal fluid 
in dogs suffering from non-infectious 
inflammatory CNS disease
Susanna Cirera1, Emilie Ulrikka Andersen‑Ranberg2, Sille Langkilde1,2, Maria Aaquist1,2 and Hanne Gredal2* 
Abstract 
Non‑infectious inflammatory (NII) central nervous system (CNS) conditions are primarily diagnosed by the demon‑
stration of inflammatory changes in the cerebrospinal fluid (CSF). However, less‑invasive methods and peripheral 
biomarkers are desired. Changes in circulating microRNA (miRNA), which are short non‑coding regulatory RNAs, 
may serve as biomarkers of disease. The aim of this pilot study was to investigate selected miRNAs in serum and CSF, 
hypothesizing that the levels of specific miRNAs in serum correlate with their presence in CSF, and that changes in 
serum miRNAs levels may reflect CNS disease. We profiled serum and CSF samples using quantitative real‑time PCR 
(qPCR) searching for selected and previously profiled miRNAs in serum (let‑7a, let‑7c, miR‑15b, miR‑16, miR‑21, miR‑
23a, miR‑24, miR‑26a, miR‑146a, miR‑155, miR‑181c and miR‑221‑3p) and in CSF (let‑7c, miR‑16, miR‑21, miR‑24, miR‑
146a, miR‑155, miR‑181c and miR‑221‑3p) from 13 dogs with NII CNS disease and six control dogs. We demonstrated 
the presence of several miRNAs in CSF (let‑7c and miR‑21 dominating) and serum (miR‑23a and miR‑21 dominating). 
However, we generally failed to reproduce consistent results in CSF samples due to several reasons: unacceptable PCR 
efficiency, a wide variation between cDNA replicates and/or no‑amplification in qPCR suggesting very low levels of 
the investigated miRNAs in canine CSF. Serum samples performed better, and 10 miRNAs qPCR assays were qualified 
for analysis. We were nevertheless unable to detect a difference in the expression of miRNA levels between cases 
and controls. Moreover, we could not confirm the results of recent miRNA investigations of canine CNS diseases. We 
believe that these disagreements highlight the significant effect of methodological/analytical variation, rather than 
the incapacity of circulating miRNAs as biomarkers of CNS disease. A secondary aim was therefore to communicate 
methodological challenges in our study and to suggest recommendations for circulating miRNA profiling, including 
pre‑, post‑ and analytical methods based on our experience, in order to reach reproducible and comparable results in 
veterinary miRNA research.
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Findings
Non-infectious inflammatory (NII) central nervous sys-
tem (CNS) conditions, including steroid responsive 
meningitis-arteritis (SRMA) and meningoencephalitis of 
unknown origin (MUO), are common causes of severe 
neurological disease in dogs. A diagnosis is primarily 
based on cerebrospinal fluid (CSF) analysis. However, as 
CSF sampling is associated with some risk and requires 
general anesthesia, less-invasive methods and biomarkers 
are desired. MicroRNAs (miRNAs) are short non-coding 
RNAs, which play an important role in gene regulation 
of many physiological and pathological processes [1]. 
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serve as biomarkers of disease offering an opportunity to 
study disease processes by minimally invasive methods.
In veterinary medicine, miRNA profiling is still in its 
infancy, and most studies concerning miRNAs involve 
tissue or serum samples. While miRNA profiling in CSF 
has been successfully conducted in humans [2–5], to our 
knowledge only three studies in dogs are available [6–8].
The overall aim of this pilot study was to investigate the 
relative expression of selected miRNAs in serum and CSF 
from dogs with NII CNS disease in comparison with non-
affected dogs in order to evaluate the potential of miR-
NAs in serum as less-invasive biomarkers than existing 
diagnostic methods. Our hypothesis was that the levels 
of specific miRNAs in serum correlate with their levels 
in CSF and thus can reflect CNS inflammation. However, 
while conducting this work, we faced several methodo-
logical challenges. A secondary aim was therefore, based 
on our experience, to suggest best-practice methods for 
future studies of miRNA profiling in dogs.
We conducted a prospective study of dogs with NII 
CNS diseases. Thirteen dogs (eight females and five 
males) with NII CNS disease (seven with MUO and six 
with SRMA) were included in the study (exclusion and 
inclusion criteria are detailed in Additional file  1). In 
addition, six control dogs with no signs of neurological 
or systemic inflammatory disease were included (two 
females and four males) amongst dogs presented for 
euthanasia at the University Hospital for Companion 
Animals, University of Copenhagen (Additional file  1, 
Table 1).
Blood and CSF were collected from each animal (Addi-
tional file 1) and centrifuged at 2000g, 4 °C, for 15 min to 
eliminate cellular debris. Serum samples were allowed to 
clot for 15 min prior to centrifugation. Samples were vis-
ually inspected for presence of hemolysis. Supernatants 
were aliquoted (200 μL) into 1.5  mL RNase-free cryo-
tubes and frozen at − 80 °C within 2 h of collection.
Total cell-free RNA, including miRNAs, was puri-
fied from serum and CSF samples using the “miRNeasy 
serum/plasma Kit” (Qiagen, Hilden, Germany) following 
the manufacturer’s protocol with the single modification 
of adding MS2 phage RNA carrier (Roche Diagnostics, 
Hvidovre, Denmark) to the QIAzol lysis reagent (Qiagen, 
Hilden, Germany) at a concentration of 1.2 μg/1 mL, as 
recommended by Enelund et al. [9] and Andreasen et al. 
[10] to improve the amount of RNA recovered. Nanodrop 
spectrophotometer (ThermoScientific, Hvidovre, Den-
mark) was used to evaluate RNA quantity and quality.
Two and three individual cDNA syntheses were made 
from each RNA stock of CSF and serum samples, respec-
tively. 1 μL of each RNA stock was used for cDNA syn-
thesis according to Balcells et al. [11]. A synthetic miRNA 
from Caenorhabditis elegans (Cel-miR-39a) was added 
as a spike-into each sample for cDNA synthesis. Samples 
Table 1 Dogs included in the analysis, MUO (n = 7), (SRMA) (n = 6), and controls with no signs of systemic or neurological 
disease (n = 6)
MUO meningoencephalitis of unknown origin, SRMA steroid-responsive meningitis arteritis, F female, Fn female neutered, M male, Mn male neutered
Dog id Diagnosis Group Breed Age Sex
1 MUO Affected Boxer 5 years F
2 MUO Affected Chihuahua (shorthaired) 2 years 10 months F
3 MUO Affected Weimaraner 8 years 3 months M
4 MUO Affected Chihuahua mix 7 years 9 months M
5 MUO Affected Chihuahua (shorthaired) 3 years 5 months F
6 MUO Affected Border collie 7 years 5 months F
7 MUO Affected Cairn terrier 7 years 1 months F
8 SRMA Affected Shih szu 1 years F
9 SRMA Affected Chesapeake bay retriever 7 months F
10 SRMA Affected Stabyhoun 1 years 11 months M
11 SRMA Affected Boxer 1 years 9 months M
12 SRMA Affected Flat coated retriever 1 years 5 months M
13 SRMA Affected Japanese akita 1 years 2 months F
14 Chronic osteo‑arthritis, blindness Control Welsh corgi cardigan 12 years 4 months Mn
15 Behavioral Control Bull terrier 3 years 8 months Mn
16 Non spinal back pain Control Rottweiler 7 years M
17 Perianal tumor Control Miniature pinscher 13 years 4 months Fn
18 Behavioural Control Mixed medium breed 1 years 2 months F
19 Chronic osteo‑arthritis Control Bull terrier 7 years 3 months M
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were diluted eight-fold prior to qPCR processing. Pro-
filed miRNAs were selected based on relevant published 
studies (Table 2, Additional file 1). Primers (Table 2) were 
designed using the software “miR-primer” [12]. QPCR 
was performed on a MX3005P system (Agilent Tech-
nologies, Glostrup, Denmark) following the protocol 
used by Enelund et al. [9] (see details in Additional file 1). 
Raw qPCR data (Additional file 2) were initially curated 
manually according to guidelines detailed in Additional 
file  1. Subsequently, data were processed using GenEx 
Pro (Multid Analyses AB, Gothenburg, Sweden) includ-
ing efficiency correction, normalization, averaging cDNA 
replicates, fold change calculations between affected and 
control dogs and log2 transformation. A two-sided non-
parametric Mann–Whitney test was used for statistical 
comparison. P values were corrected for multiple testing.
For the CSF samples, four assays of the total eight 
tested did not result in PCR efficiency within the accept-
able range of 80–110%. Moreover, all miRNA assays 
showed inconsistency between some of the cDNA rep-
licates and had samples that did not amplify or had val-
ues below the limit of detection (LOD) (Cq values > 34 
cycles). Therefore, data from CSF samples were excluded 
from further analysis. On visual assessment let-7c and 
miR-21 showed the highest expression in CSF.
Regarding serum samples, one assay was discarded 
(miR-26a) due to lack of specificity in the melting curve 
and one assay (miR-221) was below LOD. In summary, 
expression data for 11 (including assay for Cel-miR-39a) 
of the serum assays qualified for further analysis. MiR-
23a and miR-21 were found to be the most expressed 
miRNAs in serum (all samples with Cq < 30).
In order to identify stable reference miRNAs for nor-
malization, we used GeNorm [13] and NormFinder 
[14]. These programs rendered different results, i.e. 
GeNorm identified let-7c and let-7a as feasible normal-
izers (stable), and NormFinder, miR-15b. We trialed 
both options but did not find any significant differential 
expression for any of the assayed miRNAs.
Due to the lack of statistical significance in serum 
analyses and the levels of miRNAs in CSF being too 
low for quantification, we were unable to investigate 
a possible correlation between serum and CSF for the 
studied miRNAs. Moreover, we were unable to support 
the findings of similar miRNA studies in dogs, which 
have found higher levels of miR-21 and miR-181c in 
CSF of dogs with MUO compared to dogs with other 
neurological disorders [6]. We believe that difficulties 
in replicating results between studies in the field of cir-
culating miRNAs, rely significantly on the compelling 
effect of methodological variation on results, rather 
than the incapacity of miRNAs as biomarkers of CNS 
diseases. This emphasizes the need for standardized 
methods in miRNA profiling, and there are other stud-
ies pointing in the same direction [15, 16].
Our methodological recommendations, based on 
experience from the present and previous studies, are 
described below and summarized in Table 3.
We have previously shown that different miRNAs 
degrade at different pace according to their sequence 
[9, 17]. Accordingly, it is crucial that the processing of 
all samples follow a strict protocol to ensure reproduc-
ibility. We recommend freezing samples at − 80  °C as 
soon as possible and within a standardized time frame. 
In the present study, CSF and serum samples were fro-
zen at − 80 °C within 2 h. However, most of the studies 
focusing on circulating miRNAs do not report the time 
from sampling to freezing, which is important in order 
to evaluate the credibility of the results and to ensure 
reproducibility.
Table 2 Mature sequences and forward and reverse primers for each microRNA tested
Name Mature sequence Forward primer Reverse primer
let‑7a UGA GGU AGU AGG UUG UAU AGUU GCA GTG AGG TAG TAG GTT GT GGT CCA GTT TTT TTT TTT TTT TAA CTA TAC 
let‑7c UGA GGU AGU AGG UUG UAU GGUU GCA GTG AGG TAG TAG GTT GT GGT CCA GTT TTT TTT TTT TTT TAA CCA 
miR‑15b UAG CAG CAC AUC AUG GUU UACA GCA GTA GCA GCA CATCA GGT CCA GTT TTT TTT TTT TTT TGT AA
miR‑16 UAG CAG CAC GUA AAU AUU GGCG CAG TAG CAG CAC GTA AAT ATTG CAG TTT TTT TTT TTT TTT CGC CAA 
miR‑21 UAG CUU AUC AGA CUG AUG UUGA TCA GTA GCT TAT CAG ACT GATG CGT CCA GTT TTT TTT TTT TTT TCA AC
miR‑23a AUC ACA UUG CCA GGG AUU U AGA TCA CAT TGC CAG GGA GGT CCA GTT TTT TTT TTT TTT TAA ATCC 
miR‑24 UGG CUC AGU UCA GCA GGA ACAGG AGT GGC TCA GTT CAGCA CCA GTT TTT TTT TTT TTT TCC TGT TC
miR‑26a UUC AAG UAA UCC AGG AUA GGCU GCA GTT CAA GTA ATC CAG GATAG GTC CAG TTT TTT TTT TTT TTT AGC CT
miR‑146a UGA GAA CUG AAU UCC AUG GGUU CAG TGA GAA CTG AAT TCC ATG GGT CCA GTT TTT TTT TTT TTT TAA CC
miR‑155 UUA AUG CUA AUC GUG AUA GGGGU CGC AGT TAA TGC TAA TCG TGA TAG AGG TCC AGT TTT TTT TTT TTT TTA CC
miR‑181c AAC AUU CAA CCU GUC GGU GAGUU GAA CAT TCA ACC TGT CGG T GGT CCA GTT TTT TTT TTT TTT TAA CTCA 
miR‑221‑3p AGC UAC AUU GUC UGC UGG GUUU CAG AGC TAC ATT GTC TGC TG TCC AGT TTT TTT TTT TTT TTA AAC CCA 
Cel‑miR‑39a UCA CCG GGU GUA AAU CAG CUUG GTC ACC GGG TGT AAA TCA G CCA GTT TTT TTT TTT TTT TCA AGC TG
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Centrifugation to eliminate cells and debris should be 
performed at the exact same speed, temperature and 
equipment, if possible. We were unable to find a consen-
sus of centrifugation speeds and times in previous litera-
ture but decided to follow the centrifugation procedure 
of Sørensen et al. [3] based on their repeated successful 
miRNA screening in CSF.
In the present study we assessed hemolysis by visual 
inspection only. Nevertheless, there are technical meth-
ods available, which are more accurate, e.g. spectropho-
tometric absorbance at 414 nm (absorbance peak of free 
hemoglobin) or a miR ratio between different affected/
unaffected miRNAs (e.g. miR-451a and miR-23a-3p) as 
proposed by Blondal et al. [18].
Several commercial methods for the isolation of (small) 
RNAs from body fluids are available. Our methods of 
choice, based on previous experience [9, 19] was the 
miRNeasy kit (Qiagen, Hilden, Germany). Moreover, we 
previously assessed (data not shown) that miRNA recov-
ery improves considerably with the addition of carrier 
RNA in the lysis buffer, in agreement with other studies 
[9, 10]. We strongly recommend the use of carrier during 
RNA extraction, especially from fluids expected to con-
tain low levels of miRNAs such as CSF, serum or urine.
Reverse transcriptase is highly sensitive to contami-
nants and the cDNA synthesis efficiency varies greatly 
depending on the purity of the RNA samples. Due to 
the challenges with normalization, potential prob-
lems with the cDNA synthesis must be investigated by 
performing 2–3 cDNA replicates for each RNA sam-
ple, accepting only a standard deviation (SD) between 
Cq values of the replicates of < 1. In the present study, 
the SD between replicates of cDNA synthesis from CSF 
was > 1, and data were therefore excluded from further 
analysis. Unfortunately, previous studies of miRNA 
profiling in dogs do not report technical repeats at the 
levels of cDNA; the reproducibility of these results can 
therefore not be assessed [6, 7].
Data correction by PCR efficiency is often not 
reported in miRNA profiling studies. Primers per-
forming sub or supra-optimally (PCR efficiency out of 
80–110% range) will thereby likely lead to faulty con-
clusions and should be re-designed.
A gold standard normalization strategy in profiling 
circulating miRNAs is still lacking [15]. Many stud-
ies use the spike-in miRNAs for normalization [8], 
although it is known that synthetic RNA spike-ins do 
not reveal the RNA content and quality of the biological 
sample and should only be used for the identification 
of technical outliers (see recommendations at http://
www.exiqo n.com/ls/Docum ents/Scien tific /PCR-spike 
-in-manua l.pdf ). According to MIQE guidelines [20], 
the most correct way to normalize miRNA qPCR data 
is using two or more stably expressed endogenous miR-
NAs. Standard algorithms to check stability of miRNAs 
using different mathematical approaches are available, 
however, these often yield different results. The choice 
of normalizer is therefore a subjective decision, which 
can influence the results as in the present study.
Table 3 A summary of the authors’ recommendations for standardized methods in circulating miRNA profiling
Stage Method Recommendation
Pre‑analytical Sampling Freeze samples at − 80 °C (or at least − 20 °C) as soon as possible within a standardized time range for all sam‑
ples. We suggest within 1 h
Pre‑analytical Centrifugation Centrifuge samples to eliminate circulating cells or debris under standardized settings (speed, temperature), 
using the same centrifuge if possible. We suggest 2000g, at 20–25 °C for 15 min
Pre‑analytical Hemolysis detection Inspect presence of hemolysis by spectrophotometric absorbance at 414 nm, or by monitoring qPCR miR ratio 
between miR23a and miR 451a
Pre‑analytical Carrier Use a carrier during RNA extraction, for fluids expected to contain low levels of miRNAs (such CSF, serum, urine). 
We suggest MS2 phage RNA carrier
Pre‑analytical cDNA synthesis Perform 2–3 replicates for each RNA stock to detect possible inhibitors carried over from RNA isolation
Pre‑analytical Spike‑in Use an exogenous miRNAs (e.g. Cel‑miR‑39a) to add prior to RNA isolation or cDNA synthesis to assess technical 
performance
Pre‑analytical Primers Re‑design primers with PCR efficiencies outside the range of 80–110%
Analytical Normalization For normalization, several miRNAs should be tested for stability between controls and disease samples using 
suitable software algorithms, for example GeNorm and/or NormFinder. We recommend using two or more 
miRNAs for normalization if possible
Analytical Statistics Normal distributed data: use parametric test (e.g. t‑test, ANOVA)
Data not normal distributed: use non‑parametric test (e.g. Mann–Whitney test)
Apply more complex model (seek professional statistical assistance) if the model has several confounding vari‑
ables (gender, age, etc.)
Correct P values for multiple testing
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In conclusion, we were unable to reproduce the 
results from recent veterinary studies of miRNAs 
in CNS diseases, and to demonstrate a correlation 
between the selected miRNA concentrations in serum 
and CSF of dogs with NII CNS disease. However, we 
believe in the potential of miRNAs as biomarkers of NII 
CNS disease, and therefore encourage future research 
to follow a standardized methodology for both pre-
analytical and analytical steps. We suggest recommen-
dations for best practice based on our experience to 
benefit future miRNA profiling in veterinary medicine.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1302 8‑019‑0492‑y.
Additional file 1. Details on patient recruitment, sample collection, 
profiled miRNAs, qPCR protocol, manual curation of qPCR data, including 
relevant references.
Additional file 2. Raw qPCR data from serum samples 1 and 2 are the 
two cDNA replicates; NTC, sample without template; No RT, sample done 
without PAP polymerase. The assay miR‑221‑3p was out of LOD.
Abbreviations
CNS: central nervous system; Cq: quantification cycle; CSF: cerebrospinal fluid; 
LOD: limit of detection; MIQE: minimum information for publication of quanti‑
tative real‑time PCR experiments; miRNA: microRNA; MUO: meningoencepha‑
litis of unknown origin; NII: non‑infectious inflammatory; qPCR: quantitative 
real‑time PCR; SRMA: steroid responsive meningitis‑arteritis.
Acknowledgements
The authors thank Minna Jakobsen for excellent technical assistance and 
the owners of the dogs for their consent. Bodil Cathrine Koch, DVM, ECVN 
resident, is kindly acknowledged for her assistance in the collection of CSF 
samples.
Prior publication
Data have not been published previously.
Authors’ contributions
SC, EUAR and HG developed the research concept; SL, MA, EUAR and HG 
were responsible for sample collection and storage. SC developed the miRNA 
profiling methods. SL, MA and SC were responsible for miRNA profiling. SC, 
EUAR and HG drafted the manuscript. All authors read and approved the final 
manuscript.
Funding
This work was supported by a Grant from the Danish Kennel Club and Agria 
(Project No. N2018‑0004).
Availability of data and materials
The datasets used and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
Ethics approval and consent to participate
The study was approved by The Local Administrative and Ethics Committee of 
The Department of Veterinary Clinical Sciences, University of Copenhagen; 9 




HG is Associate Editor of Acta Veterinaria Scandinavia, but has not in any way 
been involved in or interacted with the review process or editorial decision 
making. The authors declare that they have no competing interests.
Author details
1 Department of Veterinary and Animal Sciences, Faculty of Health and Medi‑
cal Sciences, University of Copenhagen, Grønnegårdsvej 3, 2nd Floor, 
1870 Frederiksberg C, Denmark. 2 Department of Veterinary Clinical Sciences, 
Faculty of Health and Medical Sciences, University of Copenhagen, Dyrlægevej 
16, 1870 Frederiksberg C, Denmark. 
Received: 23 September 2019   Accepted: 24 November 2019
References
 1. Cortez MA, Bueso‑Ramos C, Ferdin J, Lopez‑Berestein G, Sood AK, Calin 
GA. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat 
Rev Clin Oncol. 2011. https ://doi.org/10.1038/nrcli nonc.2011.76.
 2. Alexandrov PN, Dua P, Hill JM, Bhattacharjee S, Zhao Y, Lukiw WJ. micro‑
RNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid 
(CSF) and extracellular fluid (ECF). Int J Biochem Mol Biol. 2012;3:365–73.
 3. Sørensen SS, Nygaard AB, Nielsen MY, Jensen K, Christensen T. miRNA 
expression profiles in cerebrospinal fluid and blood of patients with 
acute ischemic stroke. Transl Stroke Res. 2014;5:711–8.
 4. Sørensen SS, Nygaard AB, Carlsen AL, Heegaard NHH, Bak M, Christensen 
T. Elevation of brain‑enriched miRNAs in cerebrospinal fluid of patients 
with acute ischemic stroke. Biomark Res. 2017. https ://doi.org/10.1186/
s4036 4‑017‑0104‑9.
 5. Drusco A, Bottoni A, Laganà A, Acunzo M, Fassan M, Cascione L, et al. A 
differentially expressed set of microRNAs in cerebro‑spinal fluid (CSF) can 
diagnose CNS malignancies. Oncotarget. 2015;6:20829–39.
 6. Gaitero L, Russell SJ, Monteith G, LaMarre J. Expression of microRNAs miR‑
21 and miR‑181c in cerebrospinal fluid and serum in canine meningoen‑
cephalomyelitis of unknown origin. Vet J. 2016;216:122–4.
 7. Marioni‑Henry K, Zaho D, Amengual‑Batle P, Rzechorzek NM, Clinton M. 
Expression of microRNAs in cerebrospinal fluid of dogs with central nerv‑
ous system disease. Acta Vet Scand. 2018;60:80.
 8. Vansteenkiste DP, Fenger JM, Fadda P, Martin‑Vaquero P, da Costa RC. 
MicroRNA expression in the cerebrospinal fluid of dogs with and without 
cervical spondylomyelopathy. J Vet Intern Med. 2019. https ://doi.
org/10.1111/jvim.15636 .
 9. Enelund L, Nielsen LN, Cirera S. Evaluation of microRNA stability in plasma 
and serum from healthy dogs. Microrna. 2017;6:42–52.
 10. Andreasen D, Fog JU, Biggs W, Salomon J, Dahslveen IK, Baker A, et al. 
Improved microRNA quantification in total RNA from clinical samples. 
Methods. 2010;50:S6–9.
 11. Balcells I, Cirera S, Busk PK. Specific and sensitive quantitative RT‑PCR of 
miRNAs with DNA primers. BMC Biotechnol. 2011;11:70.
 12. Busk PK. A tool for design of primers for microRNA‑specific quantitative 
RT‑qPCR. BMC Bioinf. 2014;15:1–9.
 13. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, 
et al. Accurate normalization of real‑time quantitative RT‑PCR data by 
geometric averaging of multiple internal control genes. Genome Biol. 
2002;3:4–11.
 14. Andersen CL, Jensen JL, Orntoft TF. Normalization of real‑time quantita‑
tive reverse transcription‑PCR data: a model‑based variance estimation 
approach to identify genes suited for normalization, applied to bladder 
and colon cancer data sets. Cancer Res. 2004;64:5245–50.
 15. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association 
with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 
2011. https ://doi.org/10.1016/j.critr evonc .2010.11.004.
 16. de Ronde MWJ, Ruijter JM, Moerland PD, Creemers EE, Pinto‑Sietsma SJ. 
Study design and qPCR data analysis guidelines for reliable circulating 
miRNA biomarker experiments: a review. Clin Chem. 2018;64:1308–18.
 17. López AG, Brogaard L, Heegaard PMH, Cirera S, Skovgaard K. AU Content 
in the MicroRNA sequence influences its stability after heat treatment. 
Microrna. 2019. https ://doi.org/10.2174/22115 36608 66619 01311 02252 .
Page 6 of 6Cirera et al. Acta Vet Scand           (2019) 61:57 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 18. Blondal T, Nielsen SJ, Baker A, Andreasen D, Mouritzen P, Teilum MW, et al. 
Assessing sample and miRNA profile quality in serum and plasma or 
other biofluids. Methods. 2013;59:S1–6.
 19. Jessen LR, Nielsen LN, Kieler IN, Langhorn R, Reezigt BJ, Cirera S. Stability 
and profiling of urinary microRNAs in healthy cats, cats with pyelone‑
phritis, and cats with other urological conditions. J Vet Intern Med. 2019. 
https ://doi.org/10.1111/jvim.15628 .
 20. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The 
MIQE guidelines: minimum information for publication of quantitative 
real‑time PCR experiments. Clin Chem. 2009;55:611–22.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
